Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Death/intubation 14% Improvement Relative Risk c19hcq.org Beaumont et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 296 patients in France Lower death/intubation with HCQ (not stat. sig., p=0.55) Beaumont et al., Infectious Diseases Now, doi:10.1016/j.idnow.2022.02.001 Favors HCQ Favors control
Factors associated with hospital admission and adverse outcome for COVID-19: role of social factors and medical care
Beaumont et al., Infectious Diseases Now, doi:10.1016/j.idnow.2022.02.001
Beaumont et al., Factors associated with hospital admission and adverse outcome for COVID-19: role of social factors and.., Infectious Diseases Now, doi:10.1016/j.idnow.2022.02.001
Feb 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 296 hospitalized patients in France, showing no significant difference with HCQ treatment.
risk of death/intubation, 14.1% lower, HR 0.86, p = 0.55, treatment 7 of 38 (18.4%), control 88 of 258 (34.1%), NNT 6.4, adjusted per study, odds ratio converted to relative risk, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Beaumont et al., 13 Feb 2022, retrospective, France, peer-reviewed, 22 authors, average treatment delay 6.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Journal Pre-proof Factors associated with hospital admission and adverse outcome for COVID-19: role of social factors and medical care A-L Beaumont D Vignes R Sterpu G Bussone I Kansau C Pignon R Ben Ismail M Favier J-L Molitor D Braham R Fior S Roy M Mion L Meyer M Andronikof C Damoisel P Chagué J-C Aurégan N Bourgeois-Nicolaos C Guillet-Caruba J-P Téglas S Abgrall PII: S2666-9919(22)00032-X DOI: https://doi.org/doi:10.1016/j.idnow.2022.02.001 Reference: IDNOW 4554 To appear in: Received Date: 16 April 2021 Revised Date: 10 November 2021 Accepted Date: 1 February 2022 Please cite this article as: Beaumont A-L, Vignes D, Sterpu R, Bussone G, Kansau I, Pignon C, Ben Ismail R, Favier M, Molitor J-L, Braham D, Fior R, Roy S, Mion M, Meyer L, Andronikof M, Damoisel C, Chagué P, Aurégan J-C, Bourgeois-Nicolaos N, Guillet-Caruba C, Téglas J-P, Abgrall S, Factors associated with hospital admission and adverse outcome for COVID-19: role of social factors and medical care, Infectious Diseases Now (2022), doi: https://doi.org/10.1016/j.idnow.2022.02.001 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Published by Elsevier. Factors associated with hospital admission and adverse outcome for COVID-19: role of social factors and medical care f A-L Beaumonta, D Vignesa,b, R Sterpub, G Bussoneb, I Kansaub, C Pignonb, R Ben Ismailb, M Favierb, J-L Molitorb, D Brahamb, R Fiorb, S Royc, M Miond, L Meyera,e, Pr epr oo M Andronikoff, C Damoiselg, P Chaguéa,h, J-C Aurégana,i, N Bourgeois-Nicolaosj, C Guillet-Carubaj, J-P Téglasa, S Abgralla,b aUniversité Paris-Saclay, UVSQ, INSERM U1018, CESP, Le Kremlin-Bicêtre, France; bAPHP, Hôpital Antoine Béclère, Service de Médecine Interne, Clamart, France; cAPHP, Hôpital Antoine Béclère, Pharmacie, Clamart, France; dAPHP, Hôpital Antoine Béclère, Service de Gériatrie, Clamart, France; na l eAPHP, Hôpital Bicêtre, Service de Santé Publique, Le Kremlin-Bicêtre, France; fAPHP, Hôpital Antoine Béclère, Service d'Accueil des Urgences, Clamart, France; Jo ur gAPHP, Hôpital Antoine Béclère, Service de Réanimation, Clamart, France; hAPHP, Hôpital Antoine Béclère, Service de Radiologie, Clamart, France; iAPHP, Hôpital Antoine Béclère, Service d'Orthopédie, Clamart, France; jAPHP, Hôpital Antoine Béclère, Service de Bactériologie, Clamart, France Keywords. COVID-19, socio-economic deprivation, geographical origin, corticosteroids Corresponding author: Anne-Lise Beaumont Page 1 of 29 INSERM Unit 1018, Hôpital Bicêtre, 78 avenue du Général Leclerc -Secteur Pierre Lasjaunias (Porte 89) 94270 Le Kremlin-Bicêtre f mail : annelisebeaumont@gmail.com Pr epr oo +33 682 185 183 Alternate author: Sophie Abgrall INSERM Unit 1018, Hôpital Bicêtre, 78 avenue du Général Leclerc - Secteur Pierre Lasjaunias (Porte 89) 94270 Le Kremlin-Bicêtre mail: sophie.abgrall@aphp.fr +33 6 89 60 35 08  na l Highlights Geographical origin and socio-economic deprivation were not associated..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit